MEDRx has announced that it will jointly develop with Daiichi Sankyo candidate products using its proprietary percutaneous absorption technology NCTSR (Nano Colloid Transdermal System),
MEDRx news release, February 28, 2018
MEDRx licenses percutaneous absorption technology to Daiichi Sankyo